Effect of recurrent invasive pneumococcal disease on serum anti-pneumolysin IgG titres in HIV infected adults.

Onajite M. Etuwewe, Natalie Swann, Susan Hollingshead, Helen Tolmie, Ed E. Zijlstra, Brian Faragher, Neil French, Stephen Gordon

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

We measured serum anti-pneumolysin IgG concentrations in a prospective cohort of 34 HIV infected adults who developed recurrent pneumococcal bacteraemia, and compared baseline levels with HIV positive and HIV negative control subjects that remained free of pneumococcal disease. Anti-pneumolysin concentrations in HIV positive cases and controls were higher compared to HIV negative controls. There was no significant difference in levels between HIV positive subjects who did and did not Subsequently develop pneumococcal bacteraemia (geometric means 849.1 U/ml vs. 564.6 U/ml, p=0.059). Anti-pneumolysin IgG titres before, and after the recurrent episode of pneumococcal bacteraemia did not differ significantly (p=0.95). High levels of anti-pneumolysin IgG do not predict protection from invasive pneumococcal disease or indicate that an effective immune response has occurred in HIV infected patients. (C) 2009 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)3881-3884
Number of pages4
JournalVaccine
Volume27
Issue number29
DOIs
Publication statusPublished - 12 Jun 2009

Keywords

  • HIV infection
  • Pneumococcal bacteraemia
  • Pneumolysin

Fingerprint

Dive into the research topics of 'Effect of recurrent invasive pneumococcal disease on serum anti-pneumolysin IgG titres in HIV infected adults.'. Together they form a unique fingerprint.

Cite this